DT Form 4: Director Kirsten Wolberg vests 3,981 RSUs and receives 4,111 RSU grant
Rhea-AI Filing Summary
Dynatrace director Kirsten O. Wolberg reported changes in her equity holdings. The Form 4 shows a reclassification of 3,981 previously reported unvested restricted stock units (RSUs) from the non-derivative table to the derivative table and notes that 100% of those RSUs vested on August 20, 2025. The filing also reports a grant of 4,111 new RSUs that will vest on the earlier of the one-year anniversary of grant or the 2026 annual meeting, subject to continued service. Following the reported transactions, the filing shows 23,871 shares of common stock beneficially owned and 4,111 RSUs outstanding as derivative securities.
Positive
- 100% of 3,981 previously reported RSUs vested on August 20, 2025, converting contingent awards into deliverable shares or settled value
- New grant of 4,111 RSUs establishes continued alignment of the director with shareholder interests through equity-based compensation
Negative
- None.
Insights
TL;DR: Routine director equity activity; primarily a vesting event and a standard annual RSU grant.
The Form 4 documents ordinary director compensation mechanics rather than a market-moving transaction. The filing discloses the conversion/classification of 3,981 previously reported time-based RSUs as derivative securities and confirms those RSUs vested in full on August 20, 2025. It also records a new grant of 4,111 RSUs that vest on the earlier of one year from grant or the 2026 annual meeting, contingent on continued service. Governance implications are limited: this aligns with standard director retention practices and does not indicate a change in control, unusual acceleration, or off-cycle award.
TL;DR: Compensation actions reflect scheduled vesting and a typical annual RSU grant for a director.
The transaction details match routine equity compensation administration. The filing explains that RSUs granted on August 23, 2024 vested by the earlier corporate event on August 20, 2025. The new 4,111 RSU grant establishes future pay tied to continued board service with a customary one-year or annual-meeting vesting condition. There are no cash exercise prices and the RSUs convert one-for-one into common stock, so dilution implications are small and predictable relative to regular annual grants.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 3,981 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 4,111 | $0.00 | -- |
| Exercise | Common Stock | 3,981 | $0.00 | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This Form 4 reports the moving of unvested time-based restricted stock units ("RSUs") previously reported in Table I to Table II in addition to the transactions reflected herein. Reflects a decrease of 3,981 shares of the Issuer's Common Stock representing unvested RSUs that were previously reported in Table I and are being reported in Table II of this Form 4 as derivative securities. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs do not expire. They either vest or are cancelled prior to the vesting date. As previously reported on August 27, 2024, these RSUs were granted on August 23, 2024. 100% of the RSUs granted vested on August 20, 2025, which was the earlier of the one year anniversary of the date of grant (August 23, 2025) and the date of the Issuer's 2025 Annual Meeting of Stockholders (which was held on August 20, 2025). Represents the grant of RSUs. 100% of the RSUs granted will vest on the earlier of the one year anniversary of the date of grant (August 20, 2026) and the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service as a director of the Issuer on the applicable vesting date.
